Drug Type Fusion protein |
Synonyms anti-transferrin receptor/anti-IDUA VNAR bispecific antibodies (Ossianix) |
Target |
Action inhibitors, antagonists |
Mechanism IDUA inhibitors(Alpha-L-iduronidase inhibitors), TfR1 antagonists(Transferrin receptor protein 1 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedDiscovery |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Mucopolysaccharidosis I | Discovery | United States | 15 Jul 2022 |






